Harnessing Real-World Data and advanced Outcomes Science to understand AML treatment patterns, disease progression, opportunities
Boston, MA – April 10, 2019– Concerto HealthAI, a leading Real-World Data (RWD), Artificial Intelligence (AI) technology and Outcomes Science company, announced a Real-World Evidence (RWE) initiative with Astellas Pharma Inc. to harness Concerto HealthAI’s RWD in order to help focus on and benefit patients with FLT3 mutation-positive relapsed or refractory Acute Myeloid Leukemia (AML)1.
Acute Myeloid Leukemia (AML) is a life threatening cancer that impacts the blood and bone marrow. The American Cancer Society estimates that in 2018, approximately 19,000 people will be diagnosed with AML in the U.S.2 AML has been associated with various genetic mutations, of which the most common is FLT3.3
“The aim of this advanced RWE initiative is to better understand how patients with relapsed or refractory FLT3-mutated AML across the country are being treated,” said Edward Stepanski, Ph.D., COO of Concerto HealthAI’s Outcomes Science group. “Real-world data will be analyzed to better understand how FLT3 mutation testing and treatment patterns impact disease progression, patient outcomes and, ultimately, inform opportunities to improve the quality of care.”
“AML is a difficult disease to treat. As treatment options expand for AML, it’s more important than ever to understand how alternative approaches impact outcomes and how they might be improved,” said Halit Bander, VP of Oncology, Medical Affairs, Americas, at Astellas. “Identifying the real-world impact of existing treatments is an important complement to our work developing innovative new cancer medicines for patients with urgent unmet needs.”
This innovative initiative in AML will leverage American Society of Clinical Oncology (ASCO)’s CancerLinQ Discovery ® database, which contains de-identified cancer patient records and is used by leading academic researchers, non-profit organizations, government agencies and industry. The CancerLinQ platform is designed to help providers monitor, coordinate, and improve cancer outcomes and the quality of care provided to cancer patients through the collection, aggregation, curation, and analysis of clinical and related data from providers. Concerto HealthAI has an exclusive licensing agreement with CancerLinQ to advance critical research and improve outcomes across multiple cancers.
“It is a privilege to work with Astellas to bring together our regulatory-grade RWD, eurekaHealthTM AI technologies, and Outcomes Research capabilities to advance insights and inform treatment approaches that can improve AML patient care and outcomes,” said Jeff Elton, Ph.D., CEO of Concerto HealthAI.
1 American Cancer Society. What is acute myeloid leukemia? (02-22-2016)
https://www.cancer.org/cancer/acute-myeloid-leukemia/about/what-is-aml.html. Accessed 05-10-2018.
2 American Cancer Society. Key statistics for acute myeloid leukemia (01-04-2018).
https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html. Accessed 03-12-2018.
3 Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-89.